Sphere fluidics limited

Sphere Fluidics Limited: Revolutionizing Single Cell Analysis with Microfluidic Pico Droplet Technology

Sphere Fluidics Limited is a leading biotechnology company that specializes in the development of automated high-throughput single cell analysis platforms based on microfluidic pico droplet technology. The company's innovative solutions enable researchers to analyze and isolate individual cells with unprecedented precision, speed, and efficiency, opening up new possibilities for drug discovery, diagnostics, and personalized medicine.

Founded in 2010 by a team of experts in microfluidics, biochemistry, and engineering from the University of Cambridge and Imperial College London, Sphere Fluidics has quickly established itself as a pioneer in the field of single cell analysis. Its proprietary technology platform combines advanced microfabrication techniques with cutting-edge imaging systems and bioinformatics tools to enable rapid screening of millions of cells per day.

At the heart of Sphere Fluidics' technology is its patented picodroplet generator chip. This tiny device can create millions of uniform-sized droplets per second that encapsulate individual cells or particles. Each droplet acts as a miniature reaction vessel that can be analyzed or manipulated independently using various techniques such as fluorescence microscopy, PCR amplification, or CRISPR gene editing.

Sphere Fluidics offers several products based on its picodroplet technology platform:

1) Cyto-Mine®: an integrated system for high-throughput single cell analysis and monoclonal antibody discovery. Cyto-Mine® combines picodroplet generation with fluorescence-activated cell sorting (FACS) to screen up to 40 million cells per day for desired phenotypes or functions.

2) ADEPT™: an automated system for DNA assembly and protein expression optimization using picodroplets. ADEPT™ enables rapid prototyping of genetic constructs by assembling multiple DNA fragments into plasmids within minutes instead of days.

3) SpheroID™: a 3D cell culture platform that uses picodroplets to create uniform-sized spheroids or microtissues from single cells. SpheroID™ allows researchers to mimic the complexity and heterogeneity of in vivo tissues in vitro, enabling more accurate drug testing and toxicity screening.

Sphere Fluidics' products have been adopted by leading academic institutions, pharmaceutical companies, and biotech startups worldwide. Its technology has been used for a wide range of applications such as antibody discovery, cell line development, CRISPR screening, synthetic biology, and cancer research.

What sets Sphere Fluidics apart from its competitors is its focus on automation and integration. By combining multiple steps of the single cell analysis workflow into a seamless process using picodroplets as carriers, Sphere Fluidics' systems can achieve unparalleled throughput while minimizing human error and sample loss. This makes it possible to screen large libraries of cells or molecules with high resolution and reproducibility.

In addition to its commercial products, Sphere Fluidics also offers custom services for clients who require tailored solutions for their specific research needs. Its team of experienced scientists can provide consultation on experimental design, assay development, data analysis, and bioinformatics.

Sphere Fluidics is committed to advancing the field of single cell analysis through continuous innovation and collaboration with its customers. Its vision is to empower researchers with tools that enable them to unlock the full potential of individual cells in understanding disease mechanisms and developing new therapies.

In conclusion,

Sphere Fluidics Limited is a biotechnology company that specializes in automated high-throughput single cell analysis platforms based on microfluidic pico droplet technology. The company's innovative solutions enable researchers to analyze individual cells with unprecedented precision speed efficiency opening up new possibilities for drug discovery diagnostics personalized medicine etcetera. With several products based on its patented picodroplet technology platform including Cyto-Mine® ADEPT™ SpheroID™ 3D Cell Culture Platform among others; Sphere Fluidics has established itself as a pioneer in the field of single cell analysis. Its focus on automation and integration sets it apart from its competitors, making it possible to screen large libraries of cells or molecules with high resolution and reproducibility. Sphere Fluidics is committed to advancing the field of single cell analysis through continuous innovation and collaboration with its customers.